Gustavo Viani: Does acute toxicity predict late toxicity in prostate radiotherapy?
Gustavo Viani, Professor of Radiation Oncology at Ribeirão Preto Medical School, University of Sao Paulo, posted on X about recent paper by John Nikitas et al., titled “The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials” published on The Lancet.
Authors: John Nikitas, Parsa Jamshidian, Alison C Tree, Emma Hall, David Dearnaley, Jeff M Michalski, W Robert Lee, Paul L Nguyen, Howard M Sandler, Charles N Catton, Himanshu R Lukka, Luca Incrocci, Wilma Heemsbergen, Floris J Pos, Soumyajit Roy, Shawn Malone, Eric Horwitz, Jessica Karen Wong, Stefano Arcangeli, Giuseppe Sanguineti, Tahmineh Romero, Yilun Sun, Michael L Steinberg, Luca F Valle, Joanne B Weidhaas, Daniel Spratt, Donatello Telesca, Amar U Kishan.
“Does acute toxicity predict late toxicity in prostate radiotherapy? Are IMRT/SBRT better than 3D-CRT for reducing long-term side effects?
Objective:
• Assess if acute toxicity (≤3m) predicts late toxicity (>3m) in prostate cancer
• Evaluate IMRT/SBRT vs. 3D-CRT for toxicity reduction
Methods:
• Meta-analysis (6 trials, 6,593 patients).
• CTCAE-based GU/GI toxicity assessment.
Outcomes:
• Acute toxicity predicts late toxicity (GU: 2.2x, GI: 2.5x risk).
• IMRT/SBRT reduce toxicity vs. 3D-CRT.
• Early toxicity is a critical indicator!
Takeaways:
• Acute toxicity indicates future risk
• IMRT/SBRT reduce complications
• Proactive management is essential!”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023